Study of the efficacy of sucroferric oxyhydroxide (chewable tablet) on the control of CKD-MBD and improvement of renal anemia in hemodialysis patients with hyperphosphatemia.
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 Status changed from recruiting to completed.
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.
- 20 Aug 2016 New trial record